Core Viewpoint - AIM ImmunoTech Inc. has successfully closed its rights offering, raising approximately $1.8 million to support the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][5]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - Maxim Group LLC served as the dealer-manager for the rights offering [2]. Group 2: Regulatory Information - The registration statement for the rights offering was declared effective by the SEC on February 10, 2026, with modifications made in a prospectus supplement filed on February 27, 2026 [3]. - The prospectus detailing the terms of the rights offering is available on the SEC's website [3]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on the research and development of Ampligen®, which is a dsRNA and selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials for late-stage pancreatic cancer [5].

Core Viewpoint - AIM ImmunoTech Inc. has announced preliminary results of its rights offering, estimating total subscriptions of approximately $1.8 million, aimed at funding the development of its lead product, Ampligen® for late-stage pancreatic cancer treatment [1][3]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - The closing of the rights offering is anticipated to occur on or about March 6, 2026, pending the satisfaction of all closing conditions [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), an immuno-modulator that has shown broad-spectrum activity in clinical trials for treating late-stage pancreatic cancer, a significant global health issue [7].

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, which is a significant global health issue [1][8]. Rights Offering Details - Each subscription right allows holders to purchase one unit, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, at a subscription price of $1,000 per unit [2]. - The Preferred Stock is convertible into 1,000 shares of Common Stock at the holder's option, with a conversion price of $1.00 per share [2]. - Each Warrant can be exercised for one share of Common Stock at an exercise price of $1.00 per share, valid for five years from issuance [2]. Participation Requirements - Record holders wishing to participate must submit a completed rights certificate and payment to the Subscription Agent by 5:00 p.m. Eastern Time on March 3, 2026 [3]. - Subscription rights are non-transferable and cannot be revoked once exercised [4]. Management and Regulatory Aspects - Maxim Group LLC has been appointed as the dealer-manager for the Rights Offering [5]. - The offering is conducted under a registration statement declared effective by the SEC on February 10, 2026, and is available through the SEC's website [6]. Company Overview - AIM ImmunoTech Inc. focuses on immuno-pharmaceutical research and development, particularly for Ampligen®, which is a dsRNA and selective TLR3 agonist with demonstrated activity in clinical trials [8][9].

Core Viewpoint - AIM ImmunoTech Inc. has extended the subscription period for its rights offering until March 3, 2026, to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][2]. Group 1: Rights Offering Details - The subscription period for the rights offering began on February 11, 2026, and all holders must submit a completed subscription rights certificate along with payment by the new deadline [2]. - Subscription rights are non-transferable and must be exercised during the subscription period; once exercised, they cannot be revoked or changed [2]. - AIM has appointed Maxim Group LLC as the dealer-manager for the rights offering, and inquiries can be directed to them for further information [3]. Group 2: Regulatory and Compliance Information - The registration statement for the rights offering was declared effective by the SEC on February 10, 2026, and the related prospectus is available on the SEC's website [4]. - Stockholders as of February 10, 2026, should independently assess whether to exercise their subscription rights based on the company's financial condition and prospects [6]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of Ampligen®, which is a dsRNA and selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials for late-stage pancreatic cancer [7].

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen®, aimed at treating late-stage pancreatic cancer, with an expected gross proceeds of $12 million if fully subscribed [2][5]. Group 1: Rights Offering Details - The rights offering allows holders of the company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [3][4]. - Each unit consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock, with the preferred stock convertible into 833 shares of common stock at a conversion price of $1.20 per share [4]. - The subscription rights are non-transferable and must be exercised by 5:00 p.m. Eastern Time on February 27, 2026, unless extended by the company [6]. Group 2: Financial Implications - If the rights offering is fully subscribed, the company anticipates receiving aggregate gross proceeds of $12 million [5]. - Holders who fully exercise their basic subscription rights will have the opportunity to subscribe for additional units that remain unsubscribed due to unexercised basic subscription rights [5]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), which is a highly selective TLR3 agonist immuno-modulator showing promise in treating late-stage pancreatic cancer [12].

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][10] Rights Offering Details - The rights offering allows holders of the Company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [2][4] - Each subscription right entitles the holder to purchase one unit, which consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock [3] - The preferred stock is convertible into 833 shares of common stock at a conversion price of $1.20 per share, and each warrant is exercisable for one share of common stock at the same exercise price [3] Financial Projections - If fully subscribed, the rights offering is expected to generate gross proceeds of $12 million [4] - Holders who fully exercise their basic subscription rights can subscribe for additional units that remain unsubscribed [4] Subscription Period - The subscription period commenced on February 11, 2026, and will end on February 27, 2026, unless extended by the Company [5] - Subscription rights are non-transferable and must be exercised during the subscription period [5] Management and Regulatory Information - Maxim Group LLC has been engaged as the dealer-manager for the rights offering [6] - The offering is made pursuant to a registration statement declared effective by the SEC on February 10, 2026 [7]

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise gross proceeds of $12 million for corporate purposes, including clinical trial expenses and debt repayment [1][4]. Rights Offering Details - The subscription rights are non-transferable and can be exercised from February 11, 2026, to February 27, 2026, unless extended [2][5]. - The rights offering includes an over-subscription privilege allowing holders to purchase additional unsubscribed shares, subject to pro-rata allocation if demand exceeds supply [2]. - AIM's leadership, including CEO Thomas K. Equels, has indicated a non-binding intention to participate in the rights offering [3]. Financial Use of Proceeds - The net proceeds from the rights offering will be allocated for general corporate purposes, specifically for clinical trial and manufacturing expenses related to Phase 2/3 pancreatic cancer trials, as well as repaying existing debt [4]. Important Dates - Key dates for the rights offering include: - February 9, 2026: Ownership Day for stockholder record [8] - February 10, 2026: Record Date [8] - February 11, 2026: Subscription Period Begins [8] - February 27, 2026: Subscription Period Ends [8] Registration and Compliance - A registration statement has been filed with the SEC but is not yet effective, meaning securities cannot be sold until it becomes effective [9]. - The rights offering will be conducted only through a written prospectus [9]. Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen® [11].

Core Viewpoint - AIM ImmunoTech Inc. is conducting a proposed rights offering to raise gross proceeds of $12 million, which will be used for general corporate purposes, including clinical trial expenses and debt repayment [1][5]. Rights Offering Details - The rights offering will provide one non-transferable subscription right for each share of common stock and certain options and warrants held as of the record date of February 4, 2026 [2]. - Each subscription right allows the purchase of one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock [2]. - The subscription rights are non-transferable and can be exercised from February 5, 2026, to February 23, 2026, unless extended by the company [3][6]. Leadership Participation - Certain members of AIM's leadership, including CEO Thomas K. Equels, have indicated a non-binding intention to participate in the rights offering [4]. Use of Proceeds - The net proceeds from the rights offering will be allocated for clinical trial expenses related to Phase 2/3 pancreatic cancer trials and to repay certain existing debt obligations [5]. Important Dates - Key dates for the rights offering include: - February 3, 2026: Ownership Day for stockholders of record - February 4, 2026: Record Date - February 5, 2026: Subscription Period Begins - February 23, 2026: Subscription Period Ends [7]. Information Distribution - Broadridge Corporate Issuer Solutions, LLC will mail rights certificates and a prospectus to holders of record starting on or about February 5, 2026 [8].

Core Insights - AIM ImmunoTech Inc. reported solid clinical and operational execution in Q3 2025, focusing on advancing Ampligen towards FDA approval for pancreatic cancer treatment [2] - Positive mid-year safety and efficacy data from the DURIPANC clinical trial combining Ampligen with AstraZeneca's Imfinzi were highlighted, with a year-end update expected [2] Financial Highlights - As of September 30, 2025, AIM reported cash, cash equivalents, and marketable investments of $2.4 million [8] - Research and development expenses for Q3 2025 were approximately $607,000, a decrease from $1.4 million in Q3 2024 [8] - General and administrative expenses were approximately $1.8 million for Q3 2025, down from $3.1 million in the same period of 2024 [8] - The net loss from operations for Q3 2025 was approximately $(3.3 million), or $(1.57) per share, compared to $(3.7 million), or $(6.00) per share, for Q3 2024 [8] - The company expects a monthly burn rate of approximately $550,000 while maintaining operational efficiencies [8]

Core Insights - AIM ImmunoTech Inc. is focusing on advancing clinical trials of Ampligen® for pancreatic cancer treatment, aiming for drug approval [2][4] - The company reported a bolstered cash position, with funding expected to last approximately 12 months following a public equity offering that raised $8.0 million [10] - Positive mid-year data from the Phase 2 clinical study of Ampligen® in combination with AstraZeneca's Imfinzi® shows no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) [2][10] Financial Highlights - AIM ImmunoTech closed a public equity offering, raising $8.0 million in gross proceeds [10] - The company has regained its listing status on the NYSE American [10] Clinical Development - The ongoing Phase 2 study (DURIPANC) evaluates Ampligen® combined with Imfinzi® for metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX [10] - The company has received U.S. and EU Orphan Drug designations for pancreatic cancer [10] Intellectual Property - AIM ImmunoTech has been granted U.S. patents covering methods of manufacturing therapeutic dsRNA, including Ampligen, and for its combination with PD-L1 drugs for cancer treatment [10] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® as its lead product [7]